18460452. ENGINEERED PROTEINS TO ENHANCE SENSITIVITY OF A CELL TO IL-2 simplified abstract (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY)
Contents
- 1 ENGINEERED PROTEINS TO ENHANCE SENSITIVITY OF A CELL TO IL-2
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 ENGINEERED PROTEINS TO ENHANCE SENSITIVITY OF A CELL TO IL-2 - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
ENGINEERED PROTEINS TO ENHANCE SENSITIVITY OF A CELL TO IL-2
Organization Name
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventor(s)
Kenan Christopher Garcia of Menlo Park CA (US)
Sean Parker of Palo Alto CA (US)
Jonathan Sockolosky of San Francisco CA (US)
Michael Hollander of Stanford CA (US)
ENGINEERED PROTEINS TO ENHANCE SENSITIVITY OF A CELL TO IL-2 - A simplified explanation of the abstract
This abstract first appeared for US patent application 18460452 titled 'ENGINEERED PROTEINS TO ENHANCE SENSITIVITY OF A CELL TO IL-2
Simplified Explanation
The patent application describes engineered proteins that increase a cell's sensitivity to IL-2, along with the corresponding polynucleotides and methods of use.
- Engineered proteins enhance cell sensitivity to IL-2
- Polynucleotides encoding the engineered proteins are provided
- Methods of using the engineered proteins are disclosed
Potential Applications
The technology could be applied in:
- Immunotherapy
- Cancer treatment
- Autoimmune disease therapy
Problems Solved
- Enhancing cell response to IL-2
- Improving effectiveness of IL-2-based therapies
Benefits
- Increased sensitivity to IL-2
- Enhanced therapeutic outcomes
- Potential for targeted treatments
Potential Commercial Applications
- Pharmaceutical companies for drug development
- Biotechnology firms for research and development
Possible Prior Art
Prior research on IL-2 sensitivity enhancement Studies on engineered proteins in cell signaling pathways
Unanswered Questions
How do these engineered proteins specifically enhance cell sensitivity to IL-2?
The exact mechanism of action is not detailed in the abstract. Further research may be needed to understand this aspect.
What are the potential side effects or limitations of using these engineered proteins?
The abstract does not mention any potential drawbacks or challenges associated with the technology. Further studies may be required to assess these aspects.
Original Abstract Submitted
Engineered proteins, polynucleotides encoding such proteins, and methods of use thereof are provided, which engineered proteins enhance the sensitivity of a cell to IL-2.
